2021 Oct 26;11(5):517-525." Accessed on April 3, 2024, at The BMJ - "Long term health consequences of obesity." Accessed on April 3, 2024, at American Pharmacists Association (APhA) - "Compounding FAQs." Accessed on April 3, 2024, at Centers for Disease Control and Prevention (CDC) - "How Overweight and Obesity Impacts Your Health." Accessed on June 18, 2024, at CDC - "Consequences of Obesity." Accessed on April 3, 2024, at Drugs.com - "Tirzepatide User Reviews for Diabetes, Type 2." Accessed on April 3, 2024, at National Academies Press (NAP) - "Drug Compounding: An Interactive Learning Experience." Accessed on April 3, 2024, at Accreditation Commission for Health Care (ACHC) - "Pharmacy Compounding Accreditation." Accessed on April 3, 2024, at Accreditation Council for Pharmacy Education (ACPE) - "ACPE - Continuing Pharmacy Education." Accessed on April 3, 2024, at PubMed Central (PMC) - "BMJ Open
Hair loss usually eases once weight stabilises
But not everyone wants to take medications for weight loss
Patients seeking weight loss treatment should not attempt to calculate or self-administer doses of any unlicensed injectable compound
**Based on a 6-month clinical trial (n=180) of individuals who were enrolled between FebruaryApril 2024, with overweight or obesity taking semaglutide or tirzepatide for weight loss and related outcomes through the WW Clinic Program and participating in the GLP-1 companion nutrition program